MWNA
FTH

Marshall Wace North America’s Faeth Therapeutics FTH Stock Holding History

Marshall Wace North America’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-914
Closed -$265K – 1751
2021
Q1 		$265K Buy
+914
New +$306K ﹤0.01% 1346

Other funds holding FTH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
FG
Formula Growth Montreal, Quebec, Canada $222M AUM 27.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace North America's FTH Position: Q2 2021 in Review

Marshall Wace North America sold out of Faeth Therapeutics (FTH) in Q2 2021, closing a stake of 914 shares — an estimated $265K sold.

Marshall Wace North America first reported a position in FTH in Q1 2021 and held it in 1 quarter. The position peaked at $265K in Q1 2021. 34 funds tracked by Wall St. Rank hold FTH as of Q2 2021.

  • Marshall Wace North America reported no remaining Faeth Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 914 Faeth Therapeutics shares in Q2 2021, an estimated $265K.
  • Marshall Wace North America first reported a position in Faeth Therapeutics in Q1 2021 and held it in 1 quarter.
  • Marshall Wace North America's Faeth Therapeutics position peaked at $265K in Q1 2021.
  • 34 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.